Author Topic: (Abst.) Classifying PML risk with disease modifying therapies  (Read 46 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8223
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, March 12, 2017:

Quote
Mult Scler Relat Disord. 2017 Feb;12:59-63.

Classifying PML risk with disease modifying therapies.

Berger JR

Author information



Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Gates 3W, Philadelphia, PA 19104, USA. Electronic address: joseph.berger@uphs.upenn.edu.

OBJECTIVE:

To catalogue the risk of PML with the currently available disease modifying therapies (DMTs) for multiple sclerosis (MS).

BACKGROUND:

All DMTs perturb the immune system in some fashion. Natalizumab, a highly effective DMT, has been associated with a significant risk of PML. Fingolimod and dimethyl fumarate have also been unquestionably associated with a risk of PML in the MS population. Concerns about PML risk with other DMTs have arisen due to their mechanism of action and pharmacological parallel to other agents with known PML risk. A method of contextualizing PML risk for DMTs is warranted.

METHODS:

Classification of PML risk was predicated on three criteria:: 1) whether the underlying condition being treated predisposes to PML in the absence of the drug; 2) the latency from initiation of the drug to the development of PML; and 3) the frequency with which PML is observed.

RESULTS:

Among the DMTs, natalizumab occupies a place of its own with respect to PML risk. Significantly lesser degrees of risk exist for fingolimod and dimethyl fumarate. Whether PML will be observed with other DMTs in use for MS, such as, rituximab, teriflunomide, and alemtuzumab, remains uncertain.

DISCUSSION:

A logical classification for stratifying DMT PML risk is important for both the physician and patient in contextualizing risk/benefit ratios. As additional experience accumulates regarding PML and the DMTs, this early effort will undoubtedly require revisiting.

https://www.ncbi.nlm.nih.gov/pubmed/28283109
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
41 Views
Last post June 05, 2016, 02:24:56 pm
by agate
0 Replies
34 Views
Last post March 01, 2017, 11:19:01 am
by agate
0 Replies
52 Views
Last post May 16, 2017, 11:42:43 am
by agate
0 Replies
37 Views
Last post September 26, 2017, 03:41:45 pm
by agate
0 Replies
27 Views
Last post December 13, 2017, 02:44:44 pm
by agate